期刊文献+

血小板HLA供者库的建立和应用 被引量:8

原文传递
导出
摘要 血小板输注适用于预防和治疗血小板减少或血小板功能缺陷引起的出血,是临床上重要的支持疗法。然而患者在多次输注全血、红细胞、白细胞、血小板后可产生血小板相关抗体,导致血小板输注无效。临床上有些接受随机血小板输注的患者在输注,尤其是多次输注大剂量浓缩血小板和(或)单采血小板后,其血液内血小板计数增加值明显低于临床预期,甚至部分患者的出血倾向又重复出现,致使对患者的临床治疗出现困难。这种状态称之为血小板输注无效(PTR)或血小板无效性输注。PTR可以由免疫和非免疫因素引起。前者包括患者血清中存在的抗体和血小板膜上表达的抗原结合,从而加速血小板在体内破坏。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第3期198-200,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献9

  • 1Nakazawa Y, Saito S, Hasegawa Y, et al. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia. Transfusion, 2007, 47:326-334.
  • 2Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program, 2007, 2007:172-178.
  • 3Vassallo RR Jr. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol, 2007, 14:6554563.
  • 4李勇,马学严.实用血液免疫学.1版.北京:科技出版社,2006:299-300.
  • 5Santoso S, Kiefel V. Human platelet alloantigens. Wien Klin Wochenschr, 2001, 113:806-813.
  • 6Schiffer CA, Anaerson KC, Bennett CL, et al. Platelet transfusion for patient s with cancer:clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 2001, 19: 1519- 1538.
  • 7Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunizatian and refractoriness. Blood, 2004,103 : 333-339.
  • 8Slichter S J, Davis K, Enright H,et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet ransfusion intervals in thrombocytopenic patients. Blood, 2005,105: 4106- 4114.
  • 9尤建国,宣恒报,李玉峰,汪承亚.血液病患者机采血小板输注疗效及血小板抗体分析[J].中华血液学杂志,2007,28(9):635-636. 被引量:22

二级参考文献9

  • 1唐元艳,陈燕.血液病血小板无效输注的原因探讨[J].临床血液学杂志,2005,18(4):223-225. 被引量:21
  • 2韩增红,田丁,路继莲,李健.单采血小板输注减少同种免疫反应的研究[J].中国输血杂志,1996,9(3):117-122. 被引量:24
  • 3Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood,2001, 98 : 1346-1351.
  • 4Fabris F, Scandellari R, Ruzzon E, et al. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood,200d, 103:45624564.
  • 5Alcorta 1, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol, 1996,93:220-224.
  • 6Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang, 1999,76 : 1-13.
  • 7Davoren A, Mcparland P, Crowley J, et al Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland. BJOG,2003,110:492-496.
  • 8C.Kaplan,石翠英.对血清学血小板抗体实验的评估[J].国外医学(输血及血液学分册),2000,23(4):295-296. 被引量:3
  • 9李廷孝,周青林,李新菊,闫东河.血液病多次输血者血小板抗体与血小板输注效果和反应的关系[J].中华内科杂志,2003,42(8):582-583. 被引量:10

共引文献21

同被引文献69

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部